A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28102506)

Published in EJNMMI Res on January 19, 2017

Authors

John P Crandall¹, Abdel K Tahari², Rosalyn A Juergens³, Julie R Brahmer⁴, Charles M Rudin⁵, Giuseppe Esposito⁶, Deepa S Subramaniam⁷, Michael V Knopp⁸, Nathan C Hall⁹, Prateek Gajwani¹⁰, Jeffrey P Leal¹¹, Martin A Lodge¹¹, Joo H O¹², Edward W Gabrielson¹³, Lalitha K Shankar¹⁴, Richard L Wahl¹⁵^,16

Author Affiliations

1: Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, Campus Box 8131, St. Louis, MO, 63110, USA.
2: Medical Imaging Department, King Fahad Specialist Hospital, P.O. Box 15215, Dammam, 31444-34, Saudi Arabia.
3: Juravinski Cancer Centre, McMaster University, 699 Concession Street, Fourth, Hamilton, Ontario, L8V 5C2, Canada.
4: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, CRB I Room G-94, Baltimore, MD, 21287, USA.
5: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 633 3rd Ave, New York, NY, 10017, USA.
6: Department of Radiology, Georgetown University Hospital, 3800 Reservoir Road NW CCC Bldg., Washington, DC, 20007, USA.
7: Department of Medicine, Georgetown University Hospital, 3800 Reservoir Road NW LCCC Bldg., Second Floor Pod B, Washington, DC, 20007, USA.
8: Department of Radiology, The Ohio State University, Wexner Medical Center, 395 W. 12th Ave., Room 430, Columbus, OH, 43210, USA.
9: Department of Radiology, Perelman School of Medicine, University of Pennsylvania, 116 Donner, HUP 3400 Spruce Street, Philadelphia, PA, 19104, USA.
10: The Johns Hopkins Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
11: The Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Nelson B1-160, 600 N. Wolfe St., Baltimore, MD 21287, USA.
12: Department of Nuclear Medicine, Seoul St. Mary's Hospital, Catholic Medical Center, Seocho-gu, Banpo-daero 222, Seoul, 06591, Korea.
13: Department of Pathology, Johns Hopkins University School of Medicine, 1550 Orleans Street, 304 CRB II, Baltimore, MD, 21287, USA.
14: National Cancer Institute, 6130 Executive Boulevard, MSC 7412, Bethesda, MD, 20892, USA.
15: Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Blvd, Campus Box 8131, St. Louis, MO, 63110, USA. rwahl@wustl.edu.
16: The Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Nelson B1-160, 600 N. Wolfe St., Baltimore, MD 21287, USA. rwahl@wustl.edu.

Articles cited by this ↗

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ (1995) 9.36

Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol (2000) 6.88

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med (1998) 5.14

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (2014) 3.38

Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med (2003) 3.10

Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 2.67

Regulation of human thymidine kinase during the cell cycle. J Biol Chem (1988) 2.67

In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res (2002) 2.48

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med (2005) 2.36

Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol (2003) 2.35

Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28

[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res (2008) 2.03

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol (2010) 1.70

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57

Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res (2005) 1.43

Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. Eur J Cancer (2012) 1.41

Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (1992) 1.36

Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med (2003) 1.32

Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med (2005) 1.27

18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med (2013) 1.21

Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med (2010) 1.13

Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol (2009) 1.11

Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer (2008) 0.98

Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev (1998) 0.93

Detection of colorectal cancer using ¹⁸F-FLT PET: comparison with ¹⁸F-FDG PET. Nucl Med Commun (2009) 0.87

A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. J Nucl Med (2015) 0.84

Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results. Hell J Nucl Med (2014) 0.79

Prognostic value of early response assessment using 18F-FDG PET/CT in chemotherapy-treated patients with non-small-cell lung cancer. Nucl Med Commun (2015) 0.77